Randomized trial: Trimethoprim-Sulfamethoxazole does not benefit patients with moderate and severe idiopathic pulmonary fibrosis

Effect of Co-trimoxazole (Trimethoprim-Sulfamethoxazole) vs Placebo on Death, Lung Transplant, or Hospital Admission in Patients With Moderate and Severe Idiopathic Pulmonary Fibrosis: The EME-TIPAC Randomized Clinical Trial – JAMA

Commentary: Idiopathic pulmonary fibrosis: Co-trimoxazole therapy did not prevent disease progression – MedicalResearch

Commentary on Twitter

In this RCT oral co-trimoxazole (TMP-SMX) did not reduce a composite outcome of time to death, transplant, or hospitalization vs placebo in patients w moderate- severe idiopathic pulmonary fibrosis (#IPF) https://t.co/fsNxwynG1s @MarkSpe90122390

— JAMA (@JAMA_current) December 9, 2020